Clinical trials: Staphylococcus Aureus Bacteraemia
Bacteriemia, Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection
Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia
Background Methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia is a common and serious infection, associated with significant morbidity and high mortality rates.
- Trial name
- TriPasCef (NCT07186894)
- Testing
- Antistaphylococcal penicillins, Cefazolin
- Volunteers
- 5,000 people
- Sponsor
- Central Hospital, Nancy, France
Staphylococcus Aureus, Staphylococcal Skin Infections
Rapid Test to Detect Staphylococcus Aureus in Blood and Wound Infections
The purpose of this study is to determine whether the Cepheid GeneXpert system accurately detects Methicillin-Resistant and -Susceptible Staphylococcus aureus in blood cultures and wound swabs.
- Conditions
- Staphylococcus Aureus, Staphylococcal Skin Infections, Bacteremia
- Trial name
- NCT01198262
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Michael E. DeBakey VA Medical Center
Bacterial Infections
Clinical Impact of Rapid AST Directly From Blood Cultures
Bacteremia is defined as pathogenic bacteria presence in blood as evidenced by positive blood cultures. These bacteremia have significant consequences in terms of morbidity and mortality (ref. 1,2,3).
- Trial name
- MHR-BC (NCT03992703)
- Where
- France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Fondation Hôpital Saint-Joseph
Catheter Bacteremia, Staphylococcus Aureus Infection
Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus
The primary objective of the study is to demonstrate, among patients with non-complicated CR-BSIs due to S. aureus, that a single-dose of intravenous (IV) dalbavancin 1500 mg is non-inferior to standard documented antibiotic…
- Trial name
- DALICATH (NCT05117398)
- Testing
- Dalbavancin administration, Standard antibiotic therapy
- Where
- 2 sites in France
- Volunteers
- 406 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Staphylococcus Aureus Infection
Plasma Pharmacological Monitoring of M Penicillins in Methicillin-sensitive Staphylococcus Aureus Bacteremia
The treatment of Methicillin-sensitive Staphylococcus aureus bacteremia is based on the first-line use of cefazolin or M penicillins (oxacillin and cloxacillin).
- Trial name
- DOSESACLOXA (NCT06495697)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Bacteraemia in Adults
The purpose of this evaluation is to record the management and outcome of adults with S.aureus bacteraemia (SAB) across multiple European, Asian and North American sites and to identify key quality indicators associated with…
- Trial name
- ISAC (NCT02098850)
- Where
- 24 sites in Germany, South Korea and 3 more
- Volunteers
- 2,000 people
- Sponsor
- University of Cologne
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
There is a variety of in vitro, in vivo (animal model), and human case series data which suggests that the addition of ertapenem to cefazolin could improve outcomes in methicillin-susceptible S. aureus bacteremia.
- Conditions
- Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia, Staphylococcal Sepsis, Staphylococcus Aureus Endocarditis
- Trial name
- CERT (NCT04886284)
- Testing
- Ertapenem
- Where
- 7 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Todd C. Lee MD MPH FIDSA
Bacteremia, Staphylococcal Infection
MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial
In-vitro identification of S. aureus, methicillin-sensitive S. aureus (MSSA), and methicillin-resistant S. aureus (MRSA) from positive blood cultures by MicroPhage's bacteriophage-based diagnostic platform.
- Conditions
- Bacteremia, Staphylococcal Infection, Sepsis, Infection
- Trial name
- NCT00814151
- Testing
- MicroPhage S. aureus / MSSA / MRSA Blood Culture Test (prototype)
- Where
- 3 sites in United States
- Volunteers
- 712 people
- Sponsor
- MicroPhage, Inc.
Staphylococcus Aureus Bacteremia
Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, for Treatment of Staphylococcus Aureus Bacteremia (SAB)
Hospitalized patients at least 18 years of age, with Staphylococcus aureus bacteremia (SAB) will be enrolled into the study and receive one dose of Aurexis® intravenously on Study Day 1, and will be followed until Study Day 57.
- Trial name
- NCT00198302
- Testing
- Aurexis®
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Staphylococcal Bacteraemia
DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia
This is a Phase 2b clinical study, multicenter, randomized, open-label, assessor-blinded, superiority study. The study will compare dalbavancin to standard of care antibiotic therapy for the completion of therapy in patients with…
- Trial name
- NCT04775953
- Testing
- Cefazolin, Dalbavancin, Daptomycin
- Where
- 24 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia
Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking aspirin for secondary prevention of cardiovascular events.
- Conditions
- Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bloodstream Infection
- Trial name
- Clopido-SNAP 2 (NCT06650488)
- Testing
- Clopidogrel, Aspirin
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- Todd C. Lee MD MPH FIDSA
Methicillin Susceptible Staphylococcus Aureus Septicemia, Bacteremia
Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia
The purpose of our study is to examine the effects of a second antibiotic, daptomycin, in combination with a beta lactam antibiotic on treating bloodstream infection caused by methicillin-susceptible S. aureus.
- Trial name
- DASH (NCT02972983)
- Testing
- Daptomycin
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Infection, Bacteremia
Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients
The goal of this clinical research study is to learn if Vibativ (telavancin) can help to control blood stream infections (BSIs). The safety of this treatment will also be studied.
- Trial name
- NCT01321879
- Testing
- Telavancin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Bacteremia
IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB
Patients with MRSaB have high therapeutic failure rates and mortality rates. Recent studies have shown that an elevated IL-10 level is an independent risk factor of mortality.
- Trial name
- NCT02660346
- Testing
- Daptomycin, Vancomycin, Ceftaroline
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sharp HealthCare
Bacteremia Due to Staphylococcus Aureus
Vancomycin Versus Daptomycin for the Treatment of Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia
The aim of this study is to compare the efficacy of daptomycin treatment versus vancomycin treatment in the treatment of methicillin resistant staphylococcus aureus (MRSA) bloodstream infections (BSI) due to isolates with high…
- Trial name
- NCT01975662
- Testing
- Daptomycin, Vancomycin
- Where
- Singapore
- Volunteers
- 14 people
- Sponsor
- Singapore General Hospital
Bacteremia
A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial
This is a multicenter, randomized, open-label, noninferiority trial of telavancin versus standard IV therapy control (e.g., vancomycin, daptomycin, anti-staphylococcal penicillin (PCN), or cefazolin) in the treatment of subjects…
- Trial name
- NCT02208063
- Testing
- Telavancin, Vancomycin, Daptomycin
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Cumberland Pharmaceuticals
Sepsis, Sepsis Mrsa
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
The goal of this quasi-experimental interventional study is to determine the effectiveness of a multifaceted stewardship intervention in reducing overall vancomycin use in five tertiary care Pediatric Intensive Care Units (PICU).
- Conditions
- Sepsis, Sepsis Mrsa, Sepsis Bacteremia, Antimicrobial - Induced Nephropathy
- Trial name
- REVAMP (NCT05975671)
- Testing
- Multifaceted de-implementation strategy to reduce vancomycin overuse
- Where
- 4 sites in United States
- Volunteers
- 52,500 people
- Sponsor
- Children's Hospital of Philadelphia
Staphylococcal Infections, Meningitis
Cotrimoxazole Versus Vancomycin for Invasive Methicillin-resistant Staphylococcus Aureus Infections
Methicillin-resistant Staphylococcus aureus (SA) is a major pathogen causing mainly health-care associated infections and, lately, also community acquired infections. Few treatment choices exist to treat these infections.
- Conditions
- Staphylococcal Infections, Meningitis, Sepsis, Pneumonia
- Trial name
- NCT00427076
- Testing
- Cotrimoxazole, Vancomycin
- Where
- 2 sites in Israel
- Volunteers
- 252 people
- Sponsor
- Rabin Medical Center
Staphylococcus Aureus Bacteraemia
Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia
Safety and efficacy of direct thrombin inhibitors versus enoxaparin in patients with staphylococcus aureus bacteraemia. The study hypothesizes that inhibition of the coagulase-activity of S.
- Trial name
- NCT01911624
- Testing
- direct thrombin inhibition, enoxaparin
- Where
- Belgium
- Volunteers
- 94 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Staphylococcus Aureus Bacteraemia, Staphylococcal Bacteraemia
Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia
The goal of this study is to investigate if benzylpenicillin is a better treatment option than cloxacillin in patients with penicillin-susceptible Staphylococcus aureus bacteraemia.
- Conditions
- Staphylococcus Aureus Bacteraemia, Staphylococcal Bacteraemia, Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia), Staphylococcus (S.) Aureus Infection
- Trial name
- COMeBAC (NCT06726395)
- Testing
- Penicillin G_1200mg, cloxacillin
- Where
- Sweden
- Volunteers
- 420 people
- Sponsor
- Region Skane